Biology  ||| S:0 E:8 ||| NNP
and  ||| S:8 E:12 ||| CC
markers  ||| S:12 E:20 ||| NN
of  ||| S:20 E:23 ||| IN
preeclampsia  ||| S:23 E:36 ||| JJ
Preeclampsia  ||| S:36 E:49 ||| NNP
is  ||| S:49 E:52 ||| VBZ
a  ||| S:52 E:54 ||| DT
syndrome  ||| S:54 E:63 ||| NN
specific  ||| S:63 E:72 ||| NN
of  ||| S:72 E:75 ||| IN
pregnancy  ||| S:75 E:85 ||| NN
and  ||| S:85 E:89 ||| CC
placenta  ||| S:89 E:98 ||| JJ
diagnosed  ||| S:98 E:108 ||| NN
after  ||| S:108 E:114 ||| IN
20  ||| S:114 E:117 ||| CD
WG  ||| S:117 E:120 ||| NN
on  ||| S:120 E:123 ||| IN
the  ||| S:123 E:127 ||| DT
association  ||| S:127 E:139 ||| NN
of  ||| S:139 E:142 ||| IN
an  ||| S:142 E:145 ||| DT
hypertension  ||| S:145 E:158 ||| NN
and  ||| S:158 E:162 ||| CC
a  ||| S:162 E:164 ||| DT
proteinuria ||| S:164 E:175 ||| NN
.  ||| S:175 E:177 ||| .
It  ||| S:177 E:180 ||| PRP
is  ||| S:180 E:183 ||| VBZ
responsible  ||| S:183 E:195 ||| JJ
for  ||| S:195 E:199 ||| IN
significant  ||| S:199 E:211 ||| JJ
maternal-fetal  ||| S:211 E:226 ||| JJ
morbidity  ||| S:226 E:236 ||| NN
and  ||| S:236 E:240 ||| CC
mortality  ||| S:240 E:250 ||| NN
which  ||| S:250 E:256 ||| WDT
justify  ||| S:256 E:264 ||| VBZ
the  ||| S:264 E:268 ||| DT
development  ||| S:268 E:280 ||| NN
of  ||| S:280 E:283 ||| IN
markers  ||| S:283 E:291 ||| NN
for  ||| S:291 E:295 ||| IN
screening ||| S:295 E:304 ||| NN
,  ||| S:304 E:306 ||| ,
diagnosis  ||| S:306 E:316 ||| NN
and  ||| S:316 E:320 ||| CC
prognosis ||| S:320 E:329 ||| NN
.  ||| S:329 E:331 ||| .
These  ||| S:331 E:337 ||| DT
markers  ||| S:337 E:345 ||| NNS
are  ||| S:345 E:349 ||| VBP
actors  ||| S:349 E:356 ||| NNS
or  ||| S:356 E:359 ||| CC
witnesses  ||| S:359 E:369 ||| NNS
to  ||| S:369 E:372 ||| TO
the  ||| S:372 E:376 ||| DT
various  ||| S:376 E:384 ||| JJ
stages  ||| S:384 E:391 ||| NNS
and  ||| S:391 E:395 ||| CC
mechanisms  ||| S:395 E:406 ||| NNS
of  ||| S:406 E:409 ||| IN
the  ||| S:409 E:413 ||| DT
disease  ||| S:413 E:421 ||| NNP
:  ||| S:421 E:423 ||| :
the  ||| S:423 E:427 ||| DT
initial  ||| S:427 E:435 ||| JJ
defect  ||| S:435 E:442 ||| NN
of  ||| S:442 E:445 ||| IN
trophoblast  ||| S:445 E:457 ||| JJ
invasion  ||| S:457 E:466 ||| NN
and  ||| S:466 E:470 ||| CC
remodeling  ||| S:470 E:481 ||| VBG
of  ||| S:481 E:484 ||| IN
uterine  ||| S:484 E:492 ||| JJ
arteries  ||| S:492 E:501 ||| NNS
( ||| S:501 E:502 ||| -LRB-
proteases  ||| S:502 E:512 ||| FW
[ ||| S:512 E:513 ||| -LRB-
PAPP-A ||| S:513 E:519 ||| NNP
,  ||| S:519 E:521 ||| ,
ADAM-12 ||| S:521 E:528 ||| NNP
,  ||| S:528 E:530 ||| ,
uPA ||| S:530 E:533 ||| NNP
,  ||| S:533 E:535 ||| ,
MMPs ||| S:535 E:539 ||| NNP
] ||| S:539 E:540 ||| -RRB-
,  ||| S:540 E:542 ||| ,
their  ||| S:542 E:548 ||| PRP$
inhibitors ||| S:548 E:558 ||| NN
,  ||| S:558 E:560 ||| ,
and  ||| S:560 E:564 ||| CC
angiogenic  ||| S:564 E:575 ||| JJ
factors  ||| S:575 E:583 ||| NNS
[ ||| S:583 E:584 ||| -LRB-
PlGF ||| S:584 E:588 ||| NNP
,  ||| S:588 E:590 ||| ,
sflt-1 ||| S:590 E:596 ||| NNP
,  ||| S:596 E:598 ||| ,
s-eng ||| S:598 E:603 ||| NNP
] ||| S:603 E:604 ||| -RRB-
)  ||| S:604 E:606 ||| -RRB-
which  ||| S:606 E:612 ||| WDT
induces  ||| S:612 E:620 ||| VBZ
hydrostatic  ||| S:620 E:632 ||| JJ
abnormalities  ||| S:632 E:646 ||| NNS
( ||| S:646 E:647 ||| -LRB-
uterine  ||| S:647 E:655 ||| FW
doppler ||| S:655 E:662 ||| FW
)  ||| S:662 E:664 ||| -RRB-
and  ||| S:664 E:668 ||| CC
placental  ||| S:668 E:678 ||| JJ
hypoperfusion  ||| S:678 E:692 ||| NN
with  ||| S:692 E:697 ||| IN
dysoxia  ||| S:697 E:705 ||| NNS
( ||| S:705 E:706 ||| -LRB-
HIF-1α ||| S:706 E:712 ||| NNP
)  ||| S:712 E:714 ||| -RRB-
and  ||| S:714 E:718 ||| CC
oxidative  ||| S:718 E:728 ||| JJ
stress  ||| S:728 E:735 ||| NN
( ||| S:735 E:736 ||| -LRB-
free  ||| S:736 E:741 ||| JJ
radicals ||| S:741 E:749 ||| NNS
,  ||| S:749 E:751 ||| ,
peroxynitrites ||| S:751 E:765 ||| NN
,  ||| S:765 E:767 ||| ,
oxidized  ||| S:767 E:776 ||| VBG
LDL ||| S:776 E:779 ||| NNP
) ||| S:779 E:780 ||| -RRB-
.  ||| S:780 E:782 ||| .
This  ||| S:782 E:787 ||| DT
results  ||| S:787 E:795 ||| NNS
in  ||| S:795 E:798 ||| IN
impaired  ||| S:798 E:807 ||| JJ
placental  ||| S:807 E:817 ||| JJ
functions  ||| S:817 E:827 ||| NNS
including  ||| S:827 E:837 ||| VBG
endocrine  ||| S:837 E:847 ||| NNS
and  ||| S:847 E:851 ||| CC
metabolic  ||| S:851 E:861 ||| JJ
functions  ||| S:861 E:871 ||| NNS
( ||| S:871 E:872 ||| -LRB-
hCG ||| S:872 E:875 ||| NNP
,  ||| S:875 E:877 ||| ,
leptin ||| S:877 E:883 ||| CD
)  ||| S:883 E:885 ||| -RRB-
with  ||| S:885 E:890 ||| IN
increase  ||| S:890 E:899 ||| NN
in  ||| S:899 E:902 ||| IN
placental  ||| S:902 E:912 ||| JJ
apoptosis  ||| S:912 E:922 ||| NN
and  ||| S:922 E:926 ||| CC
necrosis  ||| S:926 E:935 ||| NN
with  ||| S:935 E:940 ||| IN
the  ||| S:940 E:944 ||| DT
release  ||| S:944 E:952 ||| NN
of  ||| S:952 E:955 ||| IN
exosomes  ||| S:955 E:964 ||| NN
and  ||| S:964 E:968 ||| CC
toxic  ||| S:968 E:974 ||| JJ
placental  ||| S:974 E:984 ||| JJ
fragments  ||| S:984 E:994 ||| NNS
( ||| S:994 E:995 ||| -LRB-
STBM ||| S:995 E:999 ||| NNP
)  ||| S:999 E:1001 ||| -RRB-
and  ||| S:1001 E:1005 ||| CC
their  ||| S:1005 E:1011 ||| PRP$
content  ||| S:1011 E:1019 ||| NN
( ||| S:1019 E:1020 ||| -LRB-
RNA ||| S:1020 E:1023 ||| NNP
,  ||| S:1023 E:1025 ||| ,
DNA  ||| S:1025 E:1029 ||| NNP
and  ||| S:1029 E:1033 ||| CC
proteins ||| S:1033 E:1041 ||| NNS
) ||| S:1041 E:1042 ||| -RRB-
.  ||| S:1042 E:1044 ||| .
This  ||| S:1044 E:1049 ||| DT
fragments  ||| S:1049 E:1059 ||| NNS
amplify  ||| S:1059 E:1067 ||| VBP
the  ||| S:1067 E:1071 ||| DT
gestational  ||| S:1071 E:1083 ||| JJ
inflammation  ||| S:1083 E:1096 ||| NNS
( ||| S:1096 E:1097 ||| -LRB-
IL6 ||| S:1097 E:1100 ||| NNP
,  ||| S:1100 E:1102 ||| ,
TNFα  ||| S:1102 E:1107 ||| NNP
;  ||| S:1107 E:1109 ||| :
activation  ||| S:1109 E:1120 ||| NN
of  ||| S:1120 E:1123 ||| IN
leukocytes  ||| S:1123 E:1134 ||| NN
and  ||| S:1134 E:1138 ||| CC
macrophages  ||| S:1138 E:1150 ||| NNS
[ ||| S:1150 E:1151 ||| -LRB-
elastase ||| S:1151 E:1159 ||| UH
,  ||| S:1159 E:1161 ||| ,
neopterin ||| S:1161 E:1170 ||| CD
]  ||| S:1170 E:1172 ||| -RRB-
and  ||| S:1172 E:1176 ||| CC
complement ||| S:1176 E:1186 ||| CD
)  ||| S:1186 E:1188 ||| -RRB-
and  ||| S:1188 E:1192 ||| CC
lead  ||| S:1192 E:1197 ||| VB
to  ||| S:1197 E:1200 ||| TO
a  ||| S:1200 E:1202 ||| DT
deterioration  ||| S:1202 E:1216 ||| NN
of  ||| S:1216 E:1219 ||| IN
the  ||| S:1219 E:1223 ||| DT
maternal  ||| S:1223 E:1232 ||| JJ
endothelium  ||| S:1232 E:1244 ||| NNS
( ||| S:1244 E:1245 ||| -LRB-
vasoconstriction  ||| S:1245 E:1262 ||| FW
[ ||| S:1262 E:1263 ||| -LRB-
ET2 ||| S:1263 E:1266 ||| NNP
,  ||| S:1266 E:1268 ||| ,
TxA2 ||| S:1268 E:1272 ||| CD
] ||| S:1272 E:1273 ||| -RRB-
;  ||| S:1273 E:1275 ||| :
platelet  ||| S:1275 E:1284 ||| FW
adhesion  ||| S:1284 E:1293 ||| FW
[ ||| S:1293 E:1294 ||| -LRB-
sVCAM  ||| S:1294 E:1300 ||| NNP
-1α ||| S:1300 E:1303 ||| NNP
) ||| S:1303 E:1304 ||| -RRB-
,  ||| S:1304 E:1306 ||| ,
aggregation  ||| S:1306 E:1318 ||| NN
and  ||| S:1318 E:1322 ||| CC
activation ||| S:1322 E:1332 ||| NNS
;  ||| S:1332 E:1334 ||| :
impaired  ||| S:1334 E:1343 ||| FW
vascular  ||| S:1343 E:1352 ||| FW
permeability ||| S:1352 E:1364 ||| FW
)  ||| S:1364 E:1366 ||| -RRB-
generating  ||| S:1366 E:1377 ||| NN
edema ||| S:1377 E:1382 ||| NN
,  ||| S:1382 E:1384 ||| ,
hypertension ||| S:1384 E:1396 ||| NN
,  ||| S:1396 E:1398 ||| ,
atherosclerosis  ||| S:1398 E:1414 ||| NN
and  ||| S:1414 E:1418 ||| CC
glomerular  ||| S:1418 E:1429 ||| JJ
nephropathy  ||| S:1429 E:1441 ||| NNS
( ||| S:1441 E:1442 ||| -LRB-
proteinuria ||| S:1442 E:1453 ||| UH
,  ||| S:1453 E:1455 ||| ,
hyperuricemia ||| S:1455 E:1468 ||| CD
) ||| S:1468 E:1469 ||| -RRB-
.  ||| S:1469 E:1471 ||| .
Other  ||| S:1471 E:1477 ||| JJ
markers  ||| S:1477 E:1485 ||| JJ
such  ||| S:1485 E:1490 ||| JJ
as  ||| S:1490 E:1493 ||| IN
PP13  ||| S:1493 E:1498 ||| NNP
and  ||| S:1498 E:1502 ||| CC
PTX3  ||| S:1502 E:1507 ||| NNP
seem  ||| S:1507 E:1512 ||| VBP
of  ||| S:1512 E:1515 ||| IN
interest  ||| S:1515 E:1524 ||| NN
even  ||| S:1524 E:1529 ||| RB
if  ||| S:1529 E:1532 ||| IN
their  ||| S:1532 E:1538 ||| PRP$
functions  ||| S:1538 E:1548 ||| NNS
are  ||| S:1548 E:1552 ||| VBP
poorly  ||| S:1552 E:1559 ||| RB
understood ||| S:1559 E:1569 ||| VBN
.  ||| S:1569 E:1571 ||| .
Preeclampsia  ||| S:1571 E:1584 ||| NNP
develops  ||| S:1584 E:1593 ||| VBZ
on  ||| S:1593 E:1596 ||| IN
a  ||| S:1596 E:1598 ||| DT
predisposed  ||| S:1598 E:1610 ||| JJ
maternal  ||| S:1610 E:1619 ||| JJ
environment  ||| S:1619 E:1631 ||| NN
( ||| S:1631 E:1632 ||| -LRB-
genetic ||| S:1632 E:1639 ||| JJ
,  ||| S:1639 E:1641 ||| ,
epigenetic  ||| S:1641 E:1652 ||| JJ
infectious ||| S:1652 E:1662 ||| NN
,  ||| S:1662 E:1664 ||| ,
and  ||| S:1664 E:1668 ||| CC
endocrine  ||| S:1668 E:1678 ||| JJ
factors ||| S:1678 E:1685 ||| NNS
)  ||| S:1685 E:1687 ||| -RRB-
characterized  ||| S:1687 E:1701 ||| VBN
by  ||| S:1701 E:1704 ||| IN
a  ||| S:1704 E:1706 ||| DT
maternal  ||| S:1706 E:1715 ||| JJ
inadequacy  ||| S:1715 E:1726 ||| NN
to  ||| S:1726 E:1729 ||| TO
pregnancy ||| S:1729 E:1738 ||| NN
.  ||| S:1738 E:1740 ||| .
